ArticleFrontiers in oncology2025
A case report and literature review: Diagnosis of pelvic retroperitoneal angiomyofibroblastoma assisted by next-generation sequencing.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiomyofibroblastoma (AMFB) is a rare benign soft tissue tumor that primarily arises in the vulvovaginal region of women of reproductive age. Due to its rarity, AMFB is often overlooked in the differential diagnosis, and as such, it is not frequently encountered in clinical practice. Here, we present the case of a 29-year-old female with a pelvic retroperitoneal tumor, confirmed postoperatively as AMFB based on histopathological and immunohistochemical findings. Additionally, we highlight the utility of next-generation sequencing (NGS) as a valuable tool in the differential diagnosis of such rare tumors. Due to the tumor was located at the narrow part of the pelvis and was adjacent to important tissues and organs such as the uterus and bladder, we performed surgical resection using the Da Vinci robotic system after obtaining the patient's informed consent. The procedure was successful, with no complications observed during the three-month postoperative follow-up. Furthermore, we reviewed the literature on AMFB, focusing on reported cases to identify and summarize patient characteristics, clinical presentations, histological features, and diagnostic challenges associated with this rare tumor. We aim to offer a reference for clinicians facing similar cases, aiding in accurate diagnosis and management, while addressing the challenges posed by the rarity and diagnostic complexity of angiomyofibroblastic tumors, ultimately improving clinical outcomes and advancing knowledge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.